Skip to main content

Advertisement

SpringerLink
Log in

Vascular endothelial growth factor in ovarian cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Tumor growth requires nutrients and oxygen. Both nutrients and oxygen are provided via the vasculature. Thus, when a tumor increases in volume, new blood vessels must form and invade the expanding tumor. This process, called angiogenesis, has theoretical significance in the context of ovarian cancer for two reasons. First, the process of angiogenesis and vessel regression occurs in a tightly controlled way as part of normal ovarian function. This suggests that at least some ovarian cells are primed to produce the paracrine stimulus needed for new blood vessel growth and that, on tranformation, this capability is present early in tumor development. Second, the characteristically large size of ovarian tumors indicates that angiogenesis is mandatory to sustain the tumor. In this article, we review the experimental and clinical correlative data that support the hypothesis that ovarian cancers are highly angiogenic. Because a critical component of angiogenesis is the paracrine and autocrine production of vascular endothelial cell growth factor, there is substantial focus on this topic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1970, 285:1182–1186.

    Google Scholar 

  2. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4–6.

    Article  PubMed  CAS  Google Scholar 

  3. Campbell SC: Advances in angiogenesis research: relevance to urological oncology. J Urol 1997, 158:1663–1674.

    Article  PubMed  CAS  Google Scholar 

  4. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995, 147:9–19.

    PubMed  CAS  Google Scholar 

  5. Hall NR, Fish DE, Hunt N, et al.: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1992, 1:223–229.

    Article  PubMed  CAS  Google Scholar 

  6. Schoell WM, Pieber D, Reich O, et al.: Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer 1997, 80:2257–2262.

    Article  PubMed  CAS  Google Scholar 

  7. Abulafia O, Triest WE, Sherer DM: Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997, 177:541–547.

    Article  PubMed  CAS  Google Scholar 

  8. Brustmann H, Riss P, Naude S: The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: a quantitative histologic study. Gynecol Oncol 1997, 67:20–26.

    Article  PubMed  CAS  Google Scholar 

  9. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrine Rev 1997, 18:4–25. A good general review.

    Article  CAS  Google Scholar 

  10. Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995, 108:2369–2379.

    PubMed  CAS  Google Scholar 

  11. Senger DR, Galli SJ, Dvorak AM, et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983–985.

    Article  PubMed  CAS  Google Scholar 

  12. Nicosia RF: What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 1998, 153:11–16. Recent review article on the molecular basis for tumor angiogenesis.

    PubMed  CAS  Google Scholar 

  13. Ogawa SA, Oku A, Sawano S, et al.: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998, 273:31273–31282.

    Article  PubMed  CAS  Google Scholar 

  14. Meyer M, Clauss M, Lepple-Wienhues A, et al.: A novel vascular endothelial growth factor encoded by the Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2(KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. Embo J 1999, 18:363–374.

    Article  PubMed  CAS  Google Scholar 

  15. Wiesmann C, Fuh G, Christinger HW, et al.: Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997, 91:695–704.

    Article  PubMed  CAS  Google Scholar 

  16. Rooman I, Schuit F, Bowens L: Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. Lab Invest 1997, 76:225–232.

    PubMed  CAS  Google Scholar 

  17. Boocock CA, Charnock-Jones DS, Sharkey AM, et al.:Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87:506–516.

    Article  PubMed  CAS  Google Scholar 

  18. Liu B, Earl HM, Baban D, et al.: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Comm 1995, 217:721–727.

    Article  PubMed  CAS  Google Scholar 

  19. Katoh O, Tauchi H, Kawaishi K, et al.: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995, 55:5687–5692.

    PubMed  CAS  Google Scholar 

  20. Neeman M, Abramovitch R, Schiffenbauer YS, Tempel C:Regulation of angiogenesis by hypoxic stress: from solid tumors to the ovarian follicle. Int J Exp Pathol 1997, 78:57–70. This article provides a description of normal angiogenesis in the ovary and relates it to tumor angiogenesis.

    Article  PubMed  CAS  Google Scholar 

  21. Hirsch B, Leonhardt S, Jarry H, et al.: In vivo measurement of rat ovarian collagenolytic activities. Endocrinology 1993, 133:2761–2765.

    Article  PubMed  CAS  Google Scholar 

  22. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB: Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996, 81:353–359.

    Article  PubMed  CAS  Google Scholar 

  23. Ferrara N, Chen H, Davis-Smyth T, et al.: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998, 4:336–340.

    Article  PubMed  CAS  Google Scholar 

  24. Kamat BR, Brown LF, Manseu EJ, et al.: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells: role in corpus luteum development. Am J Pathol 1995, 146:157–165.

    PubMed  CAS  Google Scholar 

  25. Neulen J, Yan Z, Raczek S, et al.: Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995, 80:1967–1971.

    Article  PubMed  CAS  Google Scholar 

  26. Schiffenbauer YS, Abramovitch R, Meir G, et al.: Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci 1997, 94:13202–13208. This article provides clinical correlative data suggestive that increased gonadotropins contribute to angiogenesis in ovarian cancer.

    Article  Google Scholar 

  27. McLaren J, Prentice A, Charnock-Jones DS, Smith SK: Vascular endothelial growth factor (VEGF) concentrations are elevated in the peritoneal fluid of women with endometriosis. Hum Reprod 1996, 11:220–223.

    PubMed  CAS  Google Scholar 

  28. Yoneda J, Kuniyasu H, Crispens MA, et al.: Expression of angiogenesis related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998, 90:447–454.

    Article  PubMed  CAS  Google Scholar 

  29. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153:1249–1256. Evidence from this experimental study supports the importance of VEGF.

    PubMed  CAS  Google Scholar 

  30. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S:Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994, 54:276–280.

    PubMed  CAS  Google Scholar 

  31. Ishii Y: Expression and subtype analysis of vascular endothelial growth factor (VEGF) and its receptor (flt-1) in human ovarian tumors]. Nippon Sanka Fujinka Gakkai Zasshi 1995, 47:133–140.

    PubMed  CAS  Google Scholar 

  32. Abu-Jawdeh GM, Faix JD, Niloff J, et al.: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996, 74:1105–1115.

    PubMed  CAS  Google Scholar 

  33. Doldi N, Bassan M, Gulisano M, et al.: Vascular endothelial growth factor messenger ribonucleic acid expression inhuman ovarian and endometrial cancer. Gynecol Endocrinol 1996, 10:375–382.

    PubMed  CAS  Google Scholar 

  34. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB: Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996, 81:353–359.

    Article  PubMed  CAS  Google Scholar 

  35. Paley PJ, Staskus KA, Gebhard K, et al.: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80:98–106.

    Article  PubMed  CAS  Google Scholar 

  36. Sowter HM, Corps AN, Evans AL, et al.: Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997, 77:607–614.

    PubMed  CAS  Google Scholar 

  37. Yamamoto S, Konishi I, Mandai M, et al.: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer 1997, 76:1221–1227.

    PubMed  CAS  Google Scholar 

  38. Salven P, Lymboussaki A, Heikkila P, et al.: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998, 153:103–108.

    PubMed  CAS  Google Scholar 

  39. Fujimoto JH, Sakaguchi R, Hirose S, et al.: Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian cancer. Cancer 1998, 83:2528–2533.

    Article  PubMed  CAS  Google Scholar 

  40. Hartenbach EM, Olson TA, Goswitz JJ, et al.: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997, 121:169–175.

    Article  PubMed  CAS  Google Scholar 

  41. Kondo S, Asano M, Matsuo K, et al.: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994, 1211:211–214.

    Google Scholar 

  42. Dirix LY, Vermeulen PB, Pawinski A, et al.: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997, 76:238–243.

    PubMed  CAS  Google Scholar 

  43. Obermair A, Tempfer C, Hefler L, et al.: Concentration of vascular endothelial growth factor in the serum of patients with suspected ovarian cancer. Br J Cancer 1998, 77:1870–1874.

    PubMed  CAS  Google Scholar 

  44. Kraft A, Weindel K, Ochs A, et al.: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178–187.

    Article  PubMed  CAS  Google Scholar 

  45. Banks RE, Forbes MA, Kinsey SE, et al.: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998, 77:856–964.

    Google Scholar 

  46. Tempfer C, Obermair A, Hefler L, et al.:Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998, 92:360–363.

    Article  PubMed  CAS  Google Scholar 

  47. Hazelton D, Nicosia RF, Nicosia SV: Demonstration of vascular endothelial growth factor in ovarian cancer. Clin Cancer Res 1999, 5:823–829.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Ovarian Cancer Program, West 345, 7701 Burholme Avenue, 19111, Philadelphia, PA, USA

    Thomas C. Hamilton PhD

Authors
  1. Darcie A. Hazelton PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas C. Hamilton PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hazelton, D.A., Hamilton, T.C. Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1, 59–63 (1999). https://doi.org/10.1007/s11912-999-0011-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-999-0011-9

Keywords

Search

Navigation